Image pharmaphorum Editor AZ-roundtable-debate-2017 Video roundtable – Part 2 Part 2 of the roundtable video debate on the challenges to secondary prevention in current clinical practice AZ-roundtable-debate-2017 Video roundtable – Part 3 Part 3 of the roundtable video debate on the opportunity for improved secondary prevention of recurrent events among high-risk patients AZ-roundtable-interviews-2017 Video interview – Professor Evangelos Giannitsis Discussion with expert cardiologist Professor Evangelos Giannitsis AZ-roundtable-interviews-2017 Video interview – Nick Hartshorne-Evans Discussion with expert patient Nick Hartshorne-Evans Load more results
AZ-roundtable-debate-2017 Video roundtable – Part 2 Part 2 of the roundtable video debate on the challenges to secondary prevention in current clinical practice
AZ-roundtable-debate-2017 Video roundtable – Part 3 Part 3 of the roundtable video debate on the opportunity for improved secondary prevention of recurrent events among high-risk patients
AZ-roundtable-interviews-2017 Video interview – Professor Evangelos Giannitsis Discussion with expert cardiologist Professor Evangelos Giannitsis
AZ-roundtable-interviews-2017 Video interview – Nick Hartshorne-Evans Discussion with expert patient Nick Hartshorne-Evans
News Novo Nordisk beefs up in oral obesity drugs with Vivtex deal Novo Nordisk is leaving no stone unturned in its bid to maintain its position in weight-loss therapies as it signs a $2.1bn alliance with Vivtex.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
